πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8613927

High affinity human antibodies to human nerve growth factor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8586363

TAL effector-mediated DNA modification

Regents of the University of Minnesota Β· Granted Tue Nov 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8586711

Polymer-factor IX moiety conjugates

Nektar Therapeutics Β· Granted Tue Nov 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8580923

Self-assembling peptide amphiphiles and related methods for growth factor delivery

Northwestern University Β· Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8569225

Targeting complement factor H for treatment of diseases

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8569379

Use of rasagiline for the treatment of olfactory dysfunction

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8557245

Methods for treating bone cancer by administering a nerve growth factor antagonist antibod

Regents of the University of Minnesota Β· Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8529885

AAV vectors for in vivo gene therapy of rheumatoid arthritis

ACADEMISCH MEDISCH CENTRUM Β· Granted Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8519102

Polymer Factor VIII moiety conjugates

Nektar Therapeutics Β· Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8519103

Factor VII polypeptides that are modified and uses thereof

Catalyst Biosciences, Inc. Β· Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8506947

Vaccinia virus expression vector for selective replication in a tumor cell and introductio

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8507653

Factor IX moiety-polymer conjugates having a releasable linkage

Nektar Therapeutics Β· Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8501688

SCGB3A2 as a growth factor and anti-apoptotic agent

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8501740

Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inh

The Board of Regents of the University of Texas System Β· Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8501466

Vector

The Pirbright Institute Β· Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8481289

Triple acting antimicrobials that are refractory to resistance development

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8465743

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of s

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 18 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8449875

Targeting pseudotyped retroviral vectors

The Regents of the University of California Β· Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8450471

TAL effector-mediated DNA modification

Regents of the University of Minnesota Β· Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8449884

Clotting factor-fc chimeric proteins to treat hemophilia

Syntonix Pharmaceuticals, Inc. Β· Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8440431

TAL effector-mediated DNA modification

Regents of the University of Minnesota Β· Granted Tue May 14 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8440432

Tal effector-mediated DNA modification

Regents of the University of Minnesota Β· Granted Tue May 14 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8420619

Rescue of photoreceptors by intravitreal administration of an expression vector encoding a

Ceregene, Inc. Β· Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8409548

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California Β· Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted